Section Arrow
HCWB.NASDAQ
- HCW Biologics Inc.
Quotes are at least 15-min delayed:2026/11/04 19:22 EST
After Hours
Last
 1.09
+0.01 (+0.93%)
Bid
1.05
Ask
1.1
High 1.09 
Low 1.0883 
Volume 200 
Regular Hours (Closed)
Last
 1.08
-0.07 (-6.09%)
Day High 
1.15 
Prev. Close
1.15 
1-M High
1.7282 
Volume 
17.80K 
Bid
1.05
Ask
1.1
Day Low
1.08 
Open
1.1 
1-M Low
1.09 
Market Cap 
2.57M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.15 
20-SMA 1.25 
50-SMA 1.88 
52-W High 23.94 
52-W Low 1.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-16.62/-1.05
Enterprise Value
9.95M
Balance Sheet
Book Value Per Share
3.32
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
54.23K
Operating Revenue Per Share
1.71
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.11+0.3961+55.48%0.2PE
After Hours 0.9498 -0.1602 -14.43%
KPTIKaryopharm Therapeutics Inc.0.0729-0.0154-17.44%-- 
After Hours 0.0853 +0.0124 +17.01%
GERNGeron Corp1.08+0.15+16.13%-- 
After Hours 1.07 -0.01 -0.93%
INOInovio Pharmaceuticals1.62-0.04-2.41%-- 
After Hours 1.59 -0.03 -1.85%
RXRXRecursion Pharmaceuticals3.88+0.2+5.43%-- 
After Hours 3.8491 -0.0309 -0.80%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class ofdrugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discoveryand development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.